Dr. Masatoshi Tomi obtained his BS degree in Pharmaceutical Sciences from Tohoku University in 1998 and his Ph.D. degree in Pharmaceutical Sciences from Tohoku University in 2004. In 2001, he started his professional carrier as Assistant Professor of Pharmaceutical Sciences at University of Toyama (Former Toyama Medical and Pharmaceutical University). From 2006 to 2008, he worked as Postdoctoral Scholar at David Geffen School of Medicine, University of California, Los Angeles (UCLA). In 2009, he moved to Faculty of Pharmacy, Keio University where he was appointed Senior Assistant Professor (2009-2011), Associate Professor (2011-2016), and Professor (2016-present). He is a recipient of the Academy of Pharmaceutical Science and Technology, Japan (APSTJ) Award for Young Scientists in 2015 and Top Reviewer for Journal of Pharmaceutical Sciences. His present research focuses on plasma membrane transporters at the tissue barriers, especially the placental barrier, and physiology/molecular biology of the barrier function.

Juan Zhang is a PhD candidate in School of Pharmacy at Zhejiang University, advised by Professors Zhen Gu and Jinqiang Wang. She joint in the university's "Medicine + X" Talent Program, to explore cross-disciplinary innovations inhealthcare. Zhang focuses on glucose-responsive insulin delivery systems for diabetes therapy. Her work published in Nat. Biomed. Eng. and Acta Biomater. She received the National Graduate Scholarship (2024) and was honored with Zhejiang University's Top Ten Academic Achievements Award (2024). She earned the Bachelor of Science in Pharmacy from Soochow University.

Dr. Wai San Cheang is currently the Assistant Professor and Programme Director (Global Affairs) at Institute of Chinese Medical Sciences/ State Key Laboratory of Quality Research in Chinese Medicine, University of Macau. She received PhD in Physiology from the Chinese University of Hong Kong in 2014 and then had postdoctoral training at the same university and University of California, San Diego. Her research interest is vascular and metabolic biology, identifying novel biomarkers/ therapeutic targets, and pharmacological characterization of Chinese medicine. She has published more than 80 SCI-articles (h-index: 33). She had a series of high profile publications in prestigious high impact journals such as Arteriosclerosis Thrombosis and Vascular Biology, British Journal of Pharmacology, Cardiovascular Research, and Pharmacological Research. She serves as the editorial board member for Scientific Reports and Current Issues of Molecular Biology. She is the PI of 16 internal and external grants including NSFC and FDCT.

Liu focuses on improving therapeutic solutions for chronic metabolic conditions, specifically exploring innovative approaches to optimize treatment efficacy and patient convenience. By designing responsive delivery mechanisms, her work aims to enhance personalized care for individuals managing long-term health challenges. She has published more than 10 peer-reviewed papers. She has participated in the Juvenile Diabetes Research Foundation projects and the preclinical trials related to IND declaration.

Ayu Lestari is a PhD candidate in the School of Pharmacy at University of Sydney. Her current research explores the physicochemical and electrostatic properties of spray-dried powders for pulmonary applications. She is particularly interested in the effects of formulation and environmental conditions on dry powder inhaler efficiency.

Dr. Shao-Qing Cai is a professor, Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University. Dr. Cai got his Ph.D. degree at Toyama Medical and Pharmaceutical University in 1989. Since then Dr. Cai has been working at Peking University. He has published over 330 papers. He proposes the “Efficacy Theory” hypothesis of the traditional Chinese medicines (TCMs) (China J Chinese Materia Medica，2015，40（17）：3435): A TCMs exerts its action through both the additive effects of numerous effective forms (including constituents or/and their metabolites) on the same target and the synergistic effects based on the overall action of the additive effects on individual targets, and the TCMs weakens its toxicities through their toxicity scattering effects. He a vice-chairman of the Chinese Committee of Traditional Chinese and Natural Medicines, Chinese Pharmaceutical Association. He serves as a member of the Chinese Pharmacopoeia Commission.He serves as a member of the Chinese Pharmacopoeia Commission.

Alireza Meymivand is a Ph.D. student in the Department of ENT Surgery at the Adelaide Medical School. He holds a B.Sc. and M.Sc. in Chemical Engineering, with a focus on pharmaceutical processes. During his master’s studies, he developed a microfluidic device for the extraction of non-steroidal anti-inflammatory drugs (NSAIDs) from biological samples. His current research focuses on optimizing drug delivery systems for the treatment of chronic rhinosinusitis, using 3D-printed anatomical models. He is evaluating various delivery methods, including bottle-squeezed irrigation, nebulisation, and acoustically assisted drug delivery, to identify the most effective approach for post-surgical cases and different nasal geometries corresponding to specific surgical techniques. He is also investigating electrostatically enhanced nebuliser-based drug delivery to improve mucosal uptake and surface adhesion between aerosols and mucus. As part of this work, he is currently assessing the biological impact of the charging mechanism on target regions within the nasal cavity.